Restore Vision
- Academic, tech transfer
- Biotech or pharma, therapeutic R&D
Restore Vision is a clinical-stage biotech company developing RV-001, the world’s first enzyme-based optogenetic gene therapy for inherited retinal diseases. Using a proprietary chimeric rhodopsin delivered to ON-bipolar cells, RV-001 mimics natural phototransduction and offers a gene-independent approach to restoring vision.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}